Ustekinumab as part of treatment for active systemic lupus erythematosus (SLE) proved effective in a new study published in The Lancet.
The multicenter, double-blind, phase 2, randomized, controlled trial included 102 patients aged between 18 and 75 years who had received an SLE diagnosis at least three months prior. Patients received either ustekinumab (n = 60) or placebo (n = 42). After six months, 62% of the ustekinumab patients (n = 37) and 33% of the placebo group (n = 14) achieved an SRI-4 response. At least one adverse event occurred in 78% of the ustekinumab patients (n = 47) and 67% of the placebo group (n = 28), the most common of which was infection (45% in the ustekinumab group [n = 27] vs 50% in the placebo group [n = 21]). During the study period there were no fatalities or treatment-emergent opportunistic infections, herpes zoster, tuberculosis, or malignancies occurred between weeks 0–24.
— Autoimmune List (@AutoimmuneList) October 2, 2018
Ustekinumab targets interleukin (IL)-12 and IL-23, both of which have been implicated in systemic lupus erythematosus, researchers note. Currently it is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn’s disease.
— Lupus News Today (@lupusnewstoday) October 1, 2018
“The addition of ustekinumab to standard-of-care treatment resulted in better efficacy in clinical and laboratory parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with ustekinumab therapy in other diseases,” the study authors concluded. “The results of this study support further development of ustekinumab as a novel treatment in systemic lupus erythematosus.”
Wow, another potential #lupus treatment on the horizon after encouraging Phase II #clinicalresearch results. It’s an exciting time for those of us with lupus. We need more effective, less toxic treatments now! #lupusresearch #hope @LADAOrg https://t.co/vM6R6AU4h8
— Kathleen Arntsen (@KathleenArntsen) September 26, 2018
Source: The Lancet